SEC Comment Letter 0000000000-24-000999 to Aditxt, Inc. (ADTX)
Aditxt, Inc.
Date: Jan. 25, 2024 · CIK: 0001726711 · Accession: 0000000000-24-000999
AI Filing Summary & Sentiment
File numbers found in text: 333-276588
Show Raw Text
United States securities and exchange commission logo
January 25, 2024
Amro Albanna
Chief Executive Officer
Aditxt, Inc.
737 N. Fifth Street, Suite 200
Richmond, VA 23219
Re:Aditxt, Inc.
Registration Statement on Form S-1
Filed January 18, 2024
File No. 333-276588
Dear Amro Albanna:
We have conducted a limited review of your registration statement and have the
following comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe this comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form S-1
General
1.It appears that you are not eligible to incorporate by reference into your Form S-1, given
that you have not filed your annual report for your most recently completed fiscal year.
Please revise your registration statement to provide all disclosure required by Form S-1 or
otherwise advise. See General Instruction VII.C to Form S-1.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
FirstName LastNameAmro Albanna
Comapany NameAditxt, Inc.
January 25, 2024 Page 2
FirstName LastName
Amro Albanna
Aditxt, Inc.
January 25, 2024
Page 2
Please contact Jimmy McNamara at 202-551-7349 or Tim Buchmiller at 202-551-3635
with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sean F. Reid, Esq.